Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
Iridex Corporation announced the publication of a two-year clinical study in the International Journal of Ophthalmology demonstrating that MicroPulse transscleral laser therapy (TLT) significantly reduces intraocular pressure and medication burden in patients with early to advanced glaucoma. The study of 84 eyes showed mean IOP reduction from 22.32 mmHg to 14.05 mmHg, with 86% success rate in POAG patients and 81% in PACG patients, with no reported complications or visual acuity reductions.